
INOVIO Advances Toward FDA Filing for INO-3107 as Quarterly Losses Narrow
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) reported second quarter 2025 financial results and outlined key milestones in its effort to bring INO-3107, a DNA medicine candidate for recurrent respiratory …
INOVIO Advances Toward FDA Filing for INO-3107 as Quarterly Losses Narrow Read More